| (210) | Number of the EPO application | 22728724 |
| (220) | Filing date of the EPO application | 2022.05.16 |
| (80) | EPO patent specification publication (B) | EPB nr. 36/2025, 2025.09.03 |
| (110) | EPO patent number | 4185318 |
| (21) | Number of the application | e 2023 0576 |
| (71) | Name(s) of applicant(s), code of the country | Regeneron Pharmaceuticals, Inc., US;
Bayer HealthCare LLC, US; |
| (72) | Name(s) of inventor(s), code of the country | VITTI Robert L., US;
BERLINER Alyson J., US;
CHU Karen, US;
ASMUS Friedrich, DE;
DA SILVA LEAL Sergio Casimiro, CH;
EISSING Thomas, DE;
RITTENHOUSE Kay D., US; |
| (73) | Name(s) of owner(s), code of the country | REGENERON PHARMACEUTICALS, INC., US;
Bayer HealthCare LLC, US; |
| (54) | Title of the invention | EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 38/17 (2006.01.01); A61P 27/02 (2006.01.01) |
| (52) | Cooperative Patent Classification | A61K 38/179 (EP); A61P 27/02 (EP) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2023.06.30 |
| (30) | Priority | 202163189541 P, 2021.05.17, US; 202163235398 P, 2021.08.20, US; 202263297420 P, 2022.01.07, US; 202263306315 P, 2022.02.03, US |
| (86) | International application | PCT/US2022/029462, 2022.05.16 |
| (87) | International publication | WO 2022/245739, 2022.11.24 |